

2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3a - Summary of and Statistical Analysis for Presence of Cough at Day 1 to 14, ITT Population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	40 (37.4%)	43 (41.0%)	83 (39.2%)
	Yes	67 (62.6%)	62 (59.0%)	129 (60.8%)
DAY 2	n	106	105	211
	No	44 (41.5%)	43 (41.0%)	87 (41.2%)
	Yes	62 (58.5%)	62 (59.0%)	124 (58.8%)
DAY 3	n	103	102	205
	No	49 (47.6%)	48 (47.1%)	97 (47.3%)
	Yes	54 (52.4%)	54 (52.9%)	108 (52.7%)
DAY 4	n	103	96	199
	No	46 (44.7%)	47 (49.0%)	93 (46.7%)
	Yes	57 (55.3%)	49 (51.0%)	106 (53.3%)
DAY 5	n	102	95	197
	No	53 (52.0%)	52 (54.7%)	105 (53.3%)
	Yes	49 (48.0%)	43 (45.3%)	92 (46.7%)
DAY 6	n	103	92	195
	No	55 (53.4%)	54 (58.7%)	109 (55.9%)
	Yes	48 (46.6%)	38 (41.3%)	86 (44.1%)
DAY 7	n	102	91	193
	No	57 (55.9%)	54 (59.3%)	111 (57.5%)
	Yes	45 (44.1%)	37 (40.7%)	82 (42.5%)
DAY 8	n	101	90	191
	No	64 (63.4%)	58 (64.4%)	122 (63.9%)
	Yes	37 (36.6%)	32 (35.6%)	69 (36.1%)
DAY 9	n	100	89	189
	No	61 (61.0%)	62 (69.7%)	123 (65.1%)
	Yes	39 (39.0%)	27 (30.3%)	66 (34.9%)

Note:



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3a - Summary of and Statistical Analysis for Presence of Cough at Day 1 to 14, ITT Population

		Placebo N=109	Hesperidin	All
		N-109	N=107	N=216
DAY 10	n	100	90	190
	No	65 (65.0%)	64 (71.1%)	129 (67.9%)
	Yes	35 (35.0%)	26 (28.9%)	61 (32.1%)
DAY 11	n	98	86	184
	No	66 (67.3%)	64 (74.4%)	130 (70.7%)
	Yes	32 (32.7%)	22 (25.6%)	54 (29.3%)
DAY 12	n	99	85	184
	No	68 (68.7%)	62 (72.9%)	130 (70.7%)
	Yes	31 (31.3%)	23 (27.1%)	54 (29.3%)
DAY 13	n	98	83	181
	No	67 (68.4%)	64 (77.1%)	131 (72.4%)
	Yes	31 (31.6%)	19 (22.9%)	50 (27.6%)
DAY 14	n	95	79	174
	No	66 (69.5%)	58 (73.4%)	124 (71.3%)
	Yes	29 (30.5%)	21 (26.6%)	50 (28.7%)

Note:



2.2 - Secondary Analysis

Table 2.2.3a - Summary of and Statistical Analysis for Presence of Cough at Day 1 to 14, ITT Population (continued)

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.02 (0.59; 1.77)	0.9416
Hesperidin vs Placebo at Day 7	0.87 (0.49; 1.55)	0.6296
Hesperidin vs Placebo at Day 10	0.75 (0.41; 1.40)	0.3711
Hesperidin vs Placebo at Day 14	0.82 (0.42; 1.61)	0.5696



2 - Efficacy Analysis 2.2 - Secondary Analysis

Table 2.2.3b - Summary of and Statistical Analysis for Presence of Fever at Day 1 to 14, ITT Population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	105	102	207
	No	100 (95.2%)	99 (97.1%)	199 (96.1%)
	Yes	5 (4.8%)	3 (2.9%)	8 (3.9%)
DAY 2	n	105	103	208
	No	101 (96.2%)	100 (97.1%)	201 (96.6%)
	Yes	4 (3.8%)	3 (2.9%)	7 (3.4%)
DAY 3	n	102	101	203
	No	96 (94.1%)	96 (95.0%)	192 (94.6%)
	Yes	6 (5.9%)	5 (5.0%)	11 (5.4%)
DAY 4	n	102	95	197
	No	99 (97.1%)	92 (96.8%)	191 (97.0%)
	Yes	3 (2.9%)	3 (3.2%)	6 (3.0%)
DAY 5	n	102	94	196
	No	98 (96.1%)	89 (94.7%)	187 (95.4%)
	Yes	4 (3.9%)	5 (5.3%)	9 (4.6%)
DAY 6	n	102	91	193
	No	99 (97.1%)	88 (96.7%)	187 (96.9%)
	Yes	3 (2.9%)	3 (3.3%)	6 (3.1%)
DAY 7	n	101	90	191
	No	97 (96.0%)	87 (96.7%)	184 (96.3%)
	Yes	4 (4.0%)	3 (3.3%)	7 (3.7%)
DAY 8	n	100	90	190
	No	97 (97.0%)	87 (96.7%)	184 (96.8%)
	Yes	3 (3.0%)	3 (3.3%)	6 (3.2%)
DAY 9	n	99	89	188
	No	98 (99.0%)	87 (97.8%)	185 (98.4%)
	Yes	1 (1.0%)	2 (2.2%)	3 (1.6%)



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3b - Summary of and Statistical Analysis for Presence of Fever at Day 1 to 14, ITT Population

		Placebo N=109	Hesperidin N=107	All N=216
		И 109	N 107	N 210
DAY 10	n	99	90	189
	No	97 (98.0%)	87 (96.7%)	184 (97.4%)
	Yes	2 (2.0%)	3 (3.3%)	5 (2.6%)
DAY 11	n	97	86	183
	No	96 (99.0%)	84 (97.7%)	180 (98.4%)
	Yes	1 (1.0%)	2 (2.3%)	3 (1.6%)
DAY 12	n	98	85	183
	No	97 (99.0%)	84 (98.8%)	181 (98.9%)
	Yes	1 (1.0%)	1 (1.2%)	2 (1.1%)
DAY 13	n	97	83	180
	No	96 (99.0%)	82 (98.8%)	178 (98.9%)
	Yes	1 (1.0%)	1 (1.2%)	2 (1.1%)
DAY 14	n	94	79	173
	No	93 (98.9%)	79 (100.0%)	172 (99.4%)
	Yes	1 (1.1%)	0 (0.0%)	1 (0.6%)

Note:



2.2 - Secondary Analysis

Table 2.2.3b - Summary of and Statistical Analysis for Presence of Fever at Day 1 to 14, ITT Population (continued)

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	0.83 (0.26; 2.67)	0.7583
Hesperidin vs Placebo at Day 7	0.84 (0.20; 3.58)	0.8091
Hesperidin vs Placebo at Day 10	1.67 (0.30; 9.42)	0.5591
Hesperidin vs Placebo at Day 14	0.00 (0.00; ND)	0.9983



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3c - Summary of and Statistical Analysis for Presence of Feverish or Chills at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	75 (70.1%)	69 (65.7%)	144 (67.9%)
	Yes	32 (29.9%)	36 (34.3%)	68 (32.1%)
DAY 2	n	106	105	211
	No	82 (77.4%)	70 (66.7%)	152 (72.0%)
	Yes	24 (22.6%)	35 (33.3%)	59 (28.0%)
DAY 3	n	103	102	205
	No	82 (79.6%)	78 (76.5%)	160 (78.0%)
	Yes	21 (20.4%)	24 (23.5%)	45 (22.0%)
DAY 4	n	103	96	199
	No	89 (86.4%)	77 (80.2%)	166 (83.4%)
	Yes	14 (13.6%)	19 (19.8%)	33 (16.6%)
DAY 5	n	102	95	197
	No	89 (87.3%)	79 (83.2%)	168 (85.3%)
	Yes	13 (12.7%)	16 (16.8%)	29 (14.7%)
DAY 6	n	103	92	195
	No	93 (90.3%)	79 (85.9%)	172 (88.2%)
	Yes	10 (9.7%)	13 (14.1%)	23 (11.8%)
DAY 7	n	102	91	193
	No	92 (90.2%)	81 (89.0%)	173 (89.6%)
	Yes	10 (9.8%)	10 (11.0%)	20 (10.4%)
DAY 8	n	101	90	191
	No	91 (90.1%)	82 (91.1%)	173 (90.6%)
	Yes	10 (9.9%)	8 (8.9%)	18 (9.4%)
DAY 9	n	100	89	189
	No	93 (93.0%)	85 (95.5%)	178 (94.2%)
	Yes	7 (7.0%)	4 (4.5%)	11 (5.8%)
Note:			, ,	, ,

Note:



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3c - Summary of and Statistical Analysis for Presence of Feverish or Chills at Day 1 to 14, ITT population

		Placebo	Hesperidin	All
		N=109	N=107	N=216
DAY 10	n	100	90	190
	No	94 (94.0%)	86 (95.6%)	180 (94.7%)
	Yes	6 (6.0%)	4 (4.4%)	10 (5.3%)
DAY 11	n	98	86	184
	No	93 (94.9%)	83 (96.5%)	176 (95.7%)
	Yes	5 (5.1%)	3 (3.5%)	8 (4.3%)
DAY 12	n	99	85	184
	No	95 (96.0%)	83 (97.6%)	178 (96.7%)
	Yes	4 (4.0%)	2 (2.4%)	6 (3.3%)
DAY 13	n	98	83	181
	No	96 (98.0%)	82 (98.8%)	178 (98.3%)
	Yes	2 (2.0%)	1 (1.2%)	3 (1.7%)
DAY 14	n	95	79	174
	No	92 (96.8%)	78 (98.7%)	170 (97.7%)
	Yes	3 (3.2%)	1 (1.3%)	4 (2.3%)
37.1.		, ,	,	

Note:



2.2 - Secondary Analysis

Table 2.2.3c - Summary of and Statistical Analysis for Presence of Feverish or Chills at Day 1 to 14, ITT Population (continued)

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.20 (0.62; 2.34)	0.5894
Hesperidin vs Placebo at Day 7	1.14 (0.45; 2.89)	0.7887
Hesperidin vs Placebo at Day 10	0.73 (0.20; 2.70)	0.6348
Hesperidin vs Placebo at Day 14	0.39 (0.04; 3.92)	0.4257



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3d - Summary of and Statistical Analysis for Presence of Sore Throat at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	66 (61.7%)	62 (59.0%)	128 (60.4%)
	Yes	41 (38.3%)	43 (41.0%)	84 (39.6%)
DAY 2	n	106	105	211
	No	71 (67.0%)	65 (61.9%)	136 (64.5%)
	Yes	35 (33.0%)	40 (38.1%)	75 (35.5%)
DAY 3	n	103	102	205
	No	80 (77.7%)	69 (67.6%)	149 (72.7%)
	Yes	23 (22.3%)	33 (32.4%)	56 (27.3%)
DAY 4	n	103	96	199
	No	80 (77.7%)	69 (71.9%)	149 (74.9%)
	Yes	23 (22.3%)	27 (28.1%)	50 (25.1%)
DAY 5	n	102	95	197
	No	79 (77.5%)	70 (73.7%)	149 (75.6%)
	Yes	23 (22.5%)	25 (26.3%)	48 (24.4%)
DAY 6	n	103	92	195
	No	86 (83.5%)	76 (82.6%)	162 (83.1%)
	Yes	17 (16.5%)	16 (17.4%)	33 (16.9%)
DAY 7	n	102	91	193
	No	89 (87.3%)	74 (81.3%)	163 (84.5%)
	Yes	13 (12.7%)	17 (18.7%)	30 (15.5%)
DAY 8	n	101	90	191
	No	88 (87.1%)	78 (86.7%)	166 (86.9%)
	Yes	13 (12.9%)	12 (13.3%)	25 (13.1%)
DAY 9	n	100	89	189
	No	87 (87.0%)	84 (94.4%)	171 (90.5%)
	Yes	13 (13.0%)	5 (5.6%)	18 (9.5%)

Note:



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3d - Summary of and Statistical Analysis for Presence of Sore Throat at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	92 (92.0%)	84 (93.3%)	176 (92.6%)
	Yes	8 (8.0%)	6 (6.7%)	14 (7.4%)
DAY 11	n	98	86	184
	No	90 (91.8%)	82 (95.3%)	172 (93.5%)
	Yes	8 (8.2%)	4 (4.7%)	12 (6.5%)
DAY 12	n	99	85	184
	No	93 (93.9%)	81 (95.3%)	174 (94.6%)
	Yes	6 (6.1%)	4 (4.7%)	10 (5.4%)
DAY 13	n	98	83	181
	No	93 (94.9%)	81 (97.6%)	174 (96.1%)
	Yes	5 (5.1%)	2 (2.4%)	7 (3.9%)
DAY 14	n	95	79	174
	No	91 (95.8%)	76 (96.2%)	167 (96.0%)
	Yes	4 (4.2%)	3 (3.8%)	7 (4.0%)

Note:



2.2 - Secondary Analysis

Table 2.2.3d - Summary of and Statistical Analysis for Presence of Sore Throat at Day 1 to 14, ITT Population (continued)

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.66 (0.89; 3.11)	0.1113
Hesperidin vs Placebo at Day 7	1.57 (0.71; 3.47)	0.2613
Hesperidin vs Placebo at Day 10	0.82 (0.27; 2.49)	0.7273
Hesperidin vs Placebo at Day 14	0.90 (0.19; 4.19)	0.8909



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3e - Summary of and Statistical Analysis for Presence of Runny Nose at Day 1 to 14, ITT population

DAY 1			Placebo N=109	Hesperidin N=107	All N=216
DAY 2	DAY 1	n	107	105	212
DAY 2 DAY 2 DAY 3 DAY 4 DAY 4 DAY 5 DAY 5 DAY 6 DAY 6 DAY 7 DAY 8 DAY 9 DAY 9		No	57 (53.3%)	52 (49.5%)	109 (51.4%)
DAY 2 2 2 2 2 2 2 2 2 2		Yes	50 (46.7%)	53 (50.5%)	103 (48.6%)
DAY 3 n 103 102 205 NO 65 (63.1%) 54 (52.9%) 119 (58.0%) DAY 4 n 103 96 199 NO 68 (66.0%) 56 (55.3%) 124 (62.3%) NO 68 (66.0%) 56 (55.3%) 124 (62.3%) NO 70 (68.6%) 59 (62.1%) 129 (65.5%) NO 74 (71.8%) 64 (69.6%) 138 (70.8%) NO 74 (71.8%) 66 (72.5%) 146 (75.6%) NO 78 (78.4%) 66 (72.5%) 146 (75.6%) NO 78 (77.2%) 66 (72.5%) 146 (75.4%) NO 78 (77.2%) 66 (73.3%) 144 (75.4%) NO 78 (77.2%) 66 (73.3%) 144 (75.4%) NO 78 (77.2%) 66 (73.3%) 144 (75.4%) NO 78 (77.2%) 66 (75.5%) 146 (75.6%) NO 78 (77.2%) 66 (75.5%) 147 (24.4%) NO 78 (77.2%) 66 (75.5%) 147 (24.4%) NO 78 (77.2%) 66 (75.5%) <t< td=""><td>DAY 2</td><td>n</td><td>106</td><td>105</td><td>211</td></t<>	DAY 2	n	106	105	211
DAY 3		No	59 (55.7%)	50 (47.6%)	109 (51.7%)
DAY 4 n 103 96 199 No 35 (34.0%) 35 (34.0%) 36 (65.0%) 36 (42.0%) DAY 5 n 102 95 129 (65.5%) No 70 (68.6%) 59 (62.1%) 129 (65.5%) No 32 (31.4%) 36 (37.9%) 68 (34.5%) DAY 6 n 103 92 195 No 74 (71.8%) 64 (69.6%) 138 (70.8%) Yes 29 (28.2%) 28 (30.4%) 57 (29.2%) DAY 7 n 102 91 195 No 29 (28.2%) 28 (30.4%) 57 (29.2%) DAY 8 n 102 91 193 No 22 (21.6%) 25 (27.5%) 146 (75.6%) PAY 9 n 78 (77.2%) 66 (73.3%) 147 (24.4%) DAY 9 n 78 (77.2%) 66 (73.3%) 147 (24.6%) DAY 9 n 78 (77.2%) 66 (76.4%) 146 (75.4%) DAY 9 n 78 (77.2%) 66 (76.4%) 146 (77.2%)		Yes	47 (44.3%)	55 (52.4%)	102 (48.3%)
DAY 4 103 96 199 NO 68 (66.0%) 56 (58.3%) 124 (62.3%) Yes 35 (34.0%) 40 (41.7%) 75 (37.7%) DAY 5 n 102 95 197 NO 70 (68.6%) 59 (62.1%) 129 (65.5%) Yes 103 92 195 104 74 (71.8%) 64 (69.6%) 138 (70.8%) NO 74 (71.8%) 64 (69.6%) 138 (70.8%) Yes 29 (28.2%) 28 (30.4%) 57 (29.2%) DAY 7 NO 20 (78.4%) 66 (72.5%) 146 (75.6%) NO 20 (21.6%) 25 (27.5%) 47 (24.4%) PAY 9 n 101 90 191 NO 78 (77.2%) 66 (73.3%) 144 (75.4%) NO 78 (77.2%) 66 (73.3%) 144 (75.4%) PAY 9 100 89 189 NO 78 (77.2%) 68 (76.4%) 146 (77.2%) NO 78 (77.2%) 66 (73.3%) 144 (75.4%) NO 78 (77.2%) 66 (73.3%) 144 (75.4%) NO 78 (77.2%) 68 (76.4%) 146 (77.2%)	DAY 3	n	103	102	205
DAY 4 DAY 4 DAY 5 DAY 6 DAY 7 DAY 8 DAY 9 DAY 100 BY 189 DAY 100 BY 1		No	65 (63.1%)	54 (52.9%)	119 (58.0%)
DAY 5 n 102 95 197 NO 70 (68.6%) 59 (62.1%) 129 (65.5%) NO 70 (68.6%) 59 (62.1%) 129 (65.5%) DAY 6 n 103 92 195 NO 74 (71.8%) 64 (69.6%) 138 (70.8%) Yes 29 (28.2%) 28 (30.4%) 57 (29.2%) DAY 7 n 102 91 193 NO 80 (78.4%) 66 (72.5%) 146 (75.6%) 22 (21.6%) 25 (27.5%) 47 (24.4%) DAY 8 n 101 90 191 193 144 (75.4%) <td></td> <td>Yes</td> <td>38 (36.9%)</td> <td>48 (47.1%)</td> <td>86 (42.0%)</td>		Yes	38 (36.9%)	48 (47.1%)	86 (42.0%)
DAY 5 n 102 95 197 NO 70 (68.6%) 59 (62.1%) 129 (65.5%) NO 70 (68.6%) 59 (62.1%) 129 (65.5%) DAY 6 n 103 92 195 NO 74 (71.8%) 64 (69.6%) 138 (70.8%) Yes 29 (28.2%) 28 (30.4%) 57 (29.2%) DAY 7 n 102 91 193 NO 80 (78.4%) 66 (72.5%) 146 (75.6%) 22 (21.6%) 25 (27.5%) 47 (24.4%) DAY 8 n 101 90 191 193 144 (75.4%) <td>DAY 4</td> <td>n</td> <td>103</td> <td>96</td> <td>199</td>	DAY 4	n	103	96	199
DAY 5 DAY 6 DAY 7 DAY 8 DAY 9 DAY 10 DAY 9 DAY 10 DAY 8 DAY 9 DAY 10 DAY 8 DAY 9 DAY 9 DAY 9 DAY 9 DAY 100 B DAY 10					
DAY 6 DAY 7 DAY 8 DAY 9 DAY 10 TO (68.6%) 59 (62.1%) 129 (65.5%) 129 (65.5%) 32 (31.4%) 36 (37.9%) 68 (34.5%) 6		Yes	35 (34.0%)	40 (41.7%)	
DAY 6 DAY 7 DAY 8 DAY 9 DAY 10 TO (68.6%) 59 (62.1%) 129 (65.5%) 129 (65.5%) 32 (31.4%) 36 (37.9%) 68 (34.5%) 6	DAY 5	n	102	95	197
DAY 6 DAY 7 DAY 8 DAY 9 DAY 9 DAY 9 DAY 9 DAY 9 DAY 9 DAY 10					
DAY 7 DAY 8 DAY 9 DAY 9 No Yes 102 91 193 146 (75.6%) 22 (21.6%) 25 (27.5%) 47 (24.4%) DAY 9 100 89 191 193 146 (75.6%) 25 (27.5%) 47 (24.4%) 147 (24.4%) 148 (75.4%) 25 (27.2%) 148 (75.4%) 25 (27.5%) 47 (24.6%) 149 (75.4%) 25 (27.5%) 47 (24.6%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%)					
DAY 7 DAY 8 DAY 9 DAY 9 No Yes 102 91 193 146 (75.6%) 22 (21.6%) 25 (27.5%) 47 (24.4%) DAY 9 100 89 191 193 146 (75.6%) 25 (27.5%) 47 (24.4%) 147 (24.4%) 148 (75.4%) 25 (27.2%) 148 (75.4%) 25 (27.5%) 47 (24.6%) 149 (75.4%) 25 (27.5%) 47 (24.6%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%) 140 (77.2%)	DAY 6	n	103	92	195
DAY 7 DAY 8 DAY 9 DAY 9 DAY 9 DAY 9 DAY 9 DAY 9 DAY 8 DAY 9 DAY 8 DAY 9 DAY 9 DAY 9 DAY 9 DAY 9 DAY 9 DAY 8 DAY 9 DAY 8 DAY 9 DAY 8 DAY 9 DAY 8 DAY 8 DAY 9 DAY 9 DAY 9 DAY 8 DAY 9 DAY 9 DAY 9 DAY 8 DAY 9 DAY 9 DAY 9 DAY 9 DAY 9 DAY 8 DAY 8 DAY 9 DAY 100 Repair A 100		No	74 (71.8%)		
DAY 9 No Yes 101 90 191 144 (75.6%) 147 (24.4%) 101 90 191 144 (75.4%) 146 (75.6%) 147 (24.4%) 101 101 101 101 101 101 101 101 101 1					
DAY 9 No Yes 101 90 191 144 (75.6%) 147 (24.4%) 101 90 191 144 (75.4%) 146 (75.6%) 147 (24.4%) 101 101 101 101 101 101 101 101 101 1	DAY 7	n	102	91	193
DAY 8 DAY 8 n NO 78 (77.2%) 66 (73.3%) 144 (75.4%) Yes DAY 9 n 100 89 189 NO 78 (78.0%) 68 (76.4%) 146 (77.2%)			80 (78.4%)		
DAY 9 No 78 (77.2%) 66 (73.3%) 24 (26.7%) 47 (24.6%) DAY 9 100 89 189 No 78 (78.0%) 68 (76.4%) 146 (77.2%)					
DAY 9 No 78 (77.2%) 66 (73.3%) 24 (26.7%) 47 (24.6%) DAY 9 100 89 189 No 78 (78.0%) 68 (76.4%) 146 (77.2%)	DAY 8	n	101	90	191
DAY 9 23 (22.8%) 24 (26.7%) 47 (24.6%) DAY 9 100 89 189 NO 78 (78.0%) 68 (76.4%) 146 (77.2%)					
No 78 (78.0%) 68 (76.4%) 146 (77.2%)					
No 78 (78.0%) 68 (76.4%) 146 (77.2%)	DAY 9	n	100	89	189
			22 (22.0%)	21 (23.6%)	43 (22.8%)

Note:



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3e - Summary of and Statistical Analysis for Presence of Runny Nose at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All
		N-109	N=107	N=216
DAY 10	n	100	90	190
	No	83 (83.0%)	72 (80.0%)	155 (81.6%)
	Yes	17 (17.0%)	18 (20.0%)	35 (18.4%)
DAY 11	n	98	86	184
	No	83 (84.7%)	71 (82.6%)	154 (83.7%)
	Yes	15 (15.3%)	15 (17.4%)	30 (16.3%)
DAY 12	n	99	85	184
	No	86 (86.9%)	72 (84.7%)	158 (85.9%)
	Yes	13 (13.1%)	13 (15.3%)	26 (14.1%)
DAY 13	n	98	83	181
	No	86 (87.8%)	69 (83.1%)	155 (85.6%)
	Yes	12 (12.2%)	14 (16.9%)	26 (14.4%)
DAY 14	n	95	79	174
	No	85 (89.5%)	67 (84.8%)	152 (87.4%)
	Yes	10 (10.5%)	12 (15.2%)	22 (12.6%)

Note:



2.2 - Secondary Analysis

Table 2.2.3e - Summary of and Statistical Analysis for Presence of Runny Nose at Day 1 to 14, ITT Population (continued)

	<u> </u>		
Contrast	OR (95% CI)	P-value	
Hesperidin vs Placebo at Day 3	1.52 (0.87; 2.67)	0.1438	
Hesperidin vs Placebo at Day 7	1.38 (0.71; 2.68)	0.3440	
Hesperidin vs Placebo at Day 10	1.22 (0.58; 2.56)	0.5968	
Hesperidin vs Placebo at Day 14	1.52 (0.62; 3.76)	0.3620	



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3f - Summary of and Statistical Analysis for Presence of Shortness of Breath/Difficulty Breathing at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	65 (60.7%)	54 (51.4%)	119 (56.1%)
	Yes	42 (39.3%)	51 (48.6%)	93 (43.9%)
DAY 2	n	106	105	211
	No	62 (58.5%)	52 (49.5%)	114 (54.0%)
	Yes	44 (41.5%)	53 (50.5%)	97 (46.0%)
DAY 3	n	103	102	205
	No	68 (66.0%)	56 (54.9%)	124 (60.5%)
	Yes	35 (34.0%)	46 (45.1%)	81 (39.5%)
DAY 4	n	103	96	199
	No	68 (66.0%)	58 (60.4%)	126 (63.3%)
	Yes	35 (34.0%)	38 (39.6%)	73 (36.7%)
DAY 5	n	102	95	197
	No	71 (69.6%)	56 (58.9%)	127 (64.5%)
	Yes	31 (30.4%)	39 (41.1%)	70 (35.5%)
DAY 6	n	103	92	195
	No	76 (73.8%)	56 (60.9%)	132 (67.7%)
	Yes	27 (26.2%)	36 (39.1%)	63 (32.3%)
DAY 7	n	102	91	193
	No	72 (70.6%)	63 (69.2%)	135 (69.9%)
	Yes	30 (29.4%)	28 (30.8%)	58 (30.1%)
DAY 8	n	101	90	191
	No	73 (72.3%)	63 (70.0%)	136 (71.2%)
	Yes	28 (27.7%)	27 (30.0%)	55 (28.8%)
DAY 9	n	100	89	189
	No	79 (79.0%)	64 (71.9%)	143 (75.7%)
	Yes	21 (21.0%)	25 (28.1%)	46 (24.3%)

Note:



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3f - Summary of and Statistical Analysis for Presence of Shortness of Breath/Difficulty Breathing at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	_	100	90	190
DAI 10	n No			
	No	82 (82.0%)	71 (78.9%)	153 (80.5%)
	Yes	18 (18.0%)	19 (21.1%)	37 (19.5%)
DAY 11	n	98	86	184
	No	80 (81.6%)	70 (81.4%)	150 (81.5%)
	Yes	18 (18.4%)	16 (18.6%)	34 (18.5%)
DAY 12	n	99	85	184
	No	84 (84.8%)	73 (85.9%)	157 (85.3%)
	Yes	15 (15.2%)	12 (14.1%)	27 (14.7%)
DAY 13	n	98	83	181
	No	83 (84.7%)	70 (84.3%)	153 (84.5%)
	Yes	15 (15.3%)	13 (15.7%)	28 (15.5%)
DAY 14	n	95	79	174
	No	82 (86.3%)	65 (82.3%)	147 (84.5%)
	Yes	13 (13.7%)	14 (17.7%)	27 (15.5%)

Note:



2.2 - Secondary Analysis

Table 2.2.3f - Summary of and Statistical Analysis for Presence of Shortness of Breath/Difficulty Breathing at Day 1 to 14, ITT Population (continued)

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.60 (0.90; 2.82)	0.1068
Hesperidin vs Placebo at Day 7	1.07 (0.57; 1.98)	0.8382
Hesperidin vs Placebo at Day 10	1.22 (0.59; 2.51)	0.5912
Hesperidin vs Placebo at Day 14	1.36 (0.59; 3.11)	0.4677



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3g - Summary of and Statistical Analysis for Presence of Nausea/Vomiting at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	95 (88.8%)	83 (79.0%)	178 (84.0%)
	Yes	12 (11.2%)	22 (21.0%)	34 (16.0%)
DAY 2	n	106	105	211
	No	91 (85.8%)	83 (79.0%)	174 (82.5%)
	Yes	15 (14.2%)	22 (21.0%)	37 (17.5%)
DAY 3	n	103	102	205
	No	91 (88.3%)	81 (79.4%)	172 (83.9%)
	Yes	12 (11.7%)	21 (20.6%)	33 (16.1%)
DAY 4	n	103	96	199
	No	94 (91.3%)	81 (84.4%)	175 (87.9%)
	Yes	9 (8.7%)	15 (15.6%)	24 (12.1%)
DAY 5	n	102	95	197
	No	95 (93.1%)	80 (84.2%)	175 (88.8%)
	Yes	7 (6.9%)	15 (15.8%)	22 (11.2%)
DAY 6	n	103	92	195
	No	97 (94.2%)	79 (85.9%)	176 (90.3%)
	Yes	6 (5.8%)	13 (14.1%)	19 (9.7%)
DAY 7	n	102	91	193
	No	91 (89.2%)	82 (90.1%)	173 (89.6%)
	Yes	11 (10.8%)	9 (9.9%)	20 (10.4%)
DAY 8	n	101	90	191
	No	95 (94.1%)	81 (90.0%)	176 (92.1%)
	Yes	6 (5.9%)	9 (10.0%)	15 (7.9%)
DAY 9	n	100	89	189
	No	96 (96.0%)	81 (91.0%)	177 (93.7%)
	Yes	4 (4.0%)	8 (9.0%)	12 (6.3%)

Note:



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3g - Summary of and Statistical Analysis for Presence of Nausea/Vomiting at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
		N-103	N-107	N-210
DAY 10	n	100	90	190
	No	95 (95.0%)	84 (93.3%)	179 (94.2%)
	Yes	5 (5.0%)	6 (6.7%)	11 (5.8%)
DAY 11	n	98	86	184
	No	93 (94.9%)	82 (95.3%)	175 (95.1%)
	Yes	5 (5.1%)	4 (4.7%)	9 (4.9%)
DAY 12	n	99	85	184
	No	96 (97.0%)	83 (97.6%)	179 (97.3%)
	Yes	3 (3.0%)	2 (2.4%)	5 (2.7%)
DAY 13	n	98	83	181
	No	94 (95.9%)	82 (98.8%)	176 (97.2%)
	Yes	4 (4.1%)	1 (1.2%)	5 (2.8%)
DAY 14	n	95	79	174
	No	93 (97.9%)	77 (97.5%)	170 (97.7%)
	Yes	2 (2.1%)	2 (2.5%)	4 (2.3%)

Note:



2.2 - Secondary Analysis

Table 2.2.3g - Summary of and Statistical Analysis for Presence of Nausea/Vomiting at Day 1 to 14, ITT Population (continued)

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.97 (0.91; 4.27)	0.0875
Hesperidin vs Placebo at Day 7	0.91 (0.36; 2.32)	0.8397
Hesperidin vs Placebo at Day 10	1.36 (0.40; 4.65)	0.6265
Hesperidin vs Placebo at Day 14	1.21 (0.16; 8.91)	0.8528



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3h - Summary of and Statistical Analysis for Presence of Headache at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	39 (36.4%)	38 (36.2%)	77 (36.3%)
	Yes	68 (63.6%)	67 (63.8%)	135 (63.7%)
DAY 2	n	106	105	211
	No	54 (50.9%)	49 (46.7%)	103 (48.8%)
	Yes	52 (49.1%)	56 (53.3%)	108 (51.2%)
DAY 3	n	103	102	205
	No	62 (60.2%)	54 (52.9%)	116 (56.6%)
	Yes	41 (39.8%)	48 (47.1%)	89 (43.4%)
DAY 4	n	103	96	199
	No	68 (66.0%)	53 (55.2%)	121 (60.8%)
	Yes	35 (34.0%)	43 (44.8%)	78 (39.2%)
DAY 5	n	102	95	197
-	No	66 (64.7%)	58 (61.1%)	124 (62.9%)
	Yes	36 (35.3%)	37 (38.9%)	73 (37.1%)
DAY 6	n	103	92	195
	No	73 (70.9%)	58 (63.0%)	131 (67.2%)
	Yes	30 (29.1%)	34 (37.0%)	64 (32.8%)
DAY 7	n	102	91	193
	No	68 (66.7%)	57 (62.6%)	125 (64.8%)
	Yes	34 (33.3%)	34 (37.4%)	68 (35.2%)
DAY 8	n	101	90	191
	No	74 (73.3%)	68 (75.6%)	142 (74.3%)
	Yes	27 (26.7%)	22 (24.4%)	49 (25.7%)
DAY 9	n	100	89	189
	No	79 (79.0%)	70 (78.7%)	149 (78.8%)
	Yes	21 (21.0%)	19 (21.3%)	40 (21.2%)
Notos		(171)	` - /	` '

Note:



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3h - Summary of and Statistical Analysis for Presence of Headache at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	80 (80.0%)	68 (75.6%)	148 (77.9%)
	Yes	20 (20.0%)	22 (24.4%)	42 (22.1%)
DAY 11	n	98	86	184
	No	81 (82.7%)	70 (81.4%)	151 (82.1%)
	Yes	17 (17.3%)	16 (18.6%)	33 (17.9%)
DAY 12	n	99	85	184
	No	82 (82.8%)	73 (85.9%)	155 (84.2%)
	Yes	17 (17.2%)	12 (14.1%)	29 (15.8%)
DAY 13	n	98	83	181
	No	84 (85.7%)	74 (89.2%)	158 (87.3%)
	Yes	14 (14.3%)	9 (10.8%)	23 (12.7%)
DAY 14	n	95	79	174
	No	86 (90.5%)	69 (87.3%)	155 (89.1%)
	Yes	9 (9.5%)	10 (12.7%)	19 (10.9%)

Note:



2.2 - Secondary Analysis

Table 2.2.3h - Summary of and Statistical Analysis for Presence of Headache at Day 1 to 14, ITT Population (continued)

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.34 (0.77; 2.35)	0.2983
Hesperidin vs Placebo at Day 7	1.19 (0.66; 2.16)	0.5611
Hesperidin vs Placebo at Day 10	1.29 (0.65; 2.58)	0.4643
Hesperidin vs Placebo at Day 14	1.38 (0.53; 3.62)	0.5063



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3i - Summary of and Statistical Analysis for Presence of General Weakness at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	40 (37.4%)	32 (30.5%)	72 (34.0%)
	Yes	67 (62.6%)	73 (69.5%)	140 (66.0%)
DAY 2	n	106	105	211
	No	45 (42.5%)	35 (33.3%)	80 (37.9%)
	Yes	61 (57.5%)	70 (66.7%)	131 (62.1%)
DAY 3	n	103	102	205
	No	48 (46.6%)	39 (38.2%)	87 (42.4%)
	Yes	55 (53.4%)	63 (61.8%)	118 (57.6%)
DAY 4	n	103	96	199
	No	49 (47.6%)	37 (38.5%)	86 (43.2%)
	Yes	54 (52.4%)	59 (61.5%)	113 (56.8%)
DAY 5	n	102	95	197
	No	53 (52.0%)	41 (43.2%)	94 (47.7%)
	Yes	49 (48.0%)	54 (56.8%)	103 (52.3%)
DAY 6	n	103	92	195
	No	62 (60.2%)	47 (51.1%)	109 (55.9%)
	Yes	41 (39.8%)	45 (48.9%)	86 (44.1%)
DAY 7	n	102	91	193
	No	62 (60.8%)	52 (57.1%)	114 (59.1%)
	Yes	40 (39.2%)	39 (42.9%)	79 (40.9%)
DAY 8	n	101	90	191
	No	69 (68.3%)	56 (62.2%)	125 (65.4%)
	Yes	32 (31.7%)	34 (37.8%)	66 (34.6%)
DAY 9	n	100	89	189
	No	73 (73.0%)	62 (69.7%)	135 (71.4%)
	Yes	27 (27.0%)	27 (30.3%)	54 (28.6%)
Note:		, , , ,	, ,	, ,

Note:



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3i - Summary of and Statistical Analysis for Presence of General Weakness at Day 1 to 14, ITT population

		Placebo	Hesperidin	All
-		N=109	N=107	N=216
DAY 10	n	100	90	190
	No	79 (79.0%)	70 (77.8%)	149 (78.4%)
	Yes	21 (21.0%)	20 (22.2%)	41 (21.6%)
DAY 11	n	98	86	184
	No	78 (79.6%)	67 (77.9%)	145 (78.8%)
	Yes	20 (20.4%)	19 (22.1%)	39 (21.2%)
DAY 12	n	99	85	184
	No	78 (78.8%)	69 (81.2%)	147 (79.9%)
	Yes	21 (21.2%)	16 (18.8%)	37 (20.1%)
DAY 13	n	98	83	181
	No	78 (79.6%)	68 (81.9%)	146 (80.7%)
	Yes	20 (20.4%)	15 (18.1%)	35 (19.3%)
DAY 14	n	95	79	174
	No	78 (82.1%)	65 (82.3%)	143 (82.2%)
	Yes	17 (17.9%)	14 (17.7%)	31 (17.8%)

Note:



2.2 - Secondary Analysis

Table 2.2.3i - Summary of and Statistical Analysis for Presence of General Weakness at Day 1 to 14, ITT Population (continued)

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.41 (0.80; 2.47)	0.2292
Hesperidin vs Placebo at Day 7	1.16 (0.65; 2.07)	0.6097
Hesperidin vs Placebo at Day 10	1.07 (0.54; 2.16)	0.8389
Hesperidin vs Placebo at Day 14	0.99 (0.45; 2.17)	0.9764



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3j - Summary of and Statistical Analysis for Presence of Pain at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	44 (41.1%)	43 (41.0%)	87 (41.0%)
	Yes	63 (58.9%)	62 (59.0%)	125 (59.0%)
DAY 2	n	106	105	211
	No	55 (51.9%)	47 (44.8%)	102 (48.3%)
	Yes	51 (48.1%)	58 (55.2%)	109 (51.7%)
DAY 3	n	103	102	205
	No	53 (51.5%)	58 (56.9%)	111 (54.1%)
	Yes	50 (48.5%)	44 (43.1%)	94 (45.9%)
DAY 4	n	103	96	199
	No	65 (63.1%)	63 (65.6%)	128 (64.3%)
	Yes	38 (36.9%)	33 (34.4%)	71 (35.7%)
DAY 5	n	102	95	197
	No	69 (67.6%)	68 (71.6%)	137 (69.5%)
	Yes	33 (32.4%)	27 (28.4%)	60 (30.5%)
DAY 6	n	103	92	195
2111 0	No	79 (76.7%)	71 (77.2%)	150 (76.9%)
	Yes	24 (23.3%)	21 (22.8%)	45 (23.1%)
DAY 7	n	102	91	193
,	No	79 (77.5%)	74 (81.3%)	153 (79.3%)
	Yes	23 (22.5%)	17 (18.7%)	40 (20.7%)
DAY 8	n	101	90	191
	No	82 (81.2%)	77 (85.6%)	159 (83.2%)
	Yes	19 (18.8%)	13 (14.4%)	32 (16.8%)
DAY 9	n	100	89	189
•	No	84 (84.0%)	76 (85.4%)	160 (84.7%)
	Yes	16 (16.0%)	13 (14.6%)	29 (15.3%)
Notos	100	10 (10:00)	== (=====)	25 (25:53)

Note:



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3j - Summary of and Statistical Analysis for Presence of Pain at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
		14-103	N-107	14-210
DAY 10	n	100	90	190
	No	86 (86.0%)	77 (85.6%)	163 (85.8%)
	Yes	14 (14.0%)	13 (14.4%)	27 (14.2%)
DAY 11	n	98	86	184
	No	86 (87.8%)	77 (89.5%)	163 (88.6%)
	Yes	12 (12.2%)	9 (10.5%)	21 (11.4%)
DAY 12	n	99	85	184
	No	89 (89.9%)	79 (92.9%)	168 (91.3%)
	Yes	10 (10.1%)	6 (7.1%)	16 (8.7%)
DAY 13	n	98	83	181
	No	89 (90.8%)	78 (94.0%)	167 (92.3%)
	Yes	9 (9.2%)	5 (6.0%)	14 (7.7%)
1/		0.5	5 0	454
DAY 14	n	95	79	174
	No	87 (91.6%)	74 (93.7%)	161 (92.5%)
	Yes	8 (8.4%)	5 (6.3%)	13 (7.5%)

Note:



2.2 - Secondary Analysis

Table 2.2.3j - Summary of and Statistical Analysis for Presence of Pain at Day 1 to 14, ITT Population (continued)

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	0.80 (0.46; 1.40)	0.4403
Hesperidin vs Placebo at Day 7	0.79 (0.39; 1.60)	0.5112
Hesperidin vs Placebo at Day 10	1.04 (0.46; 2.36)	0.9306
Hesperidin vs Placebo at Day 14	0.73 (0.23; 2.36)	0.6046



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3k - Summary of and Statistical Analysis for Presence of Irritability/Confusion at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	79 (73.8%)	80 (76.2%)	159 (75.0%)
	Yes	28 (26.2%)	25 (23.8%)	53 (25.0%)
DAY 2	n	106	105	211
	No	80 (75.5%)	83 (79.0%)	163 (77.3%)
	Yes	26 (24.5%)	22 (21.0%)	48 (22.7%)
DAY 3	n	103	102	205
	No	85 (82.5%)	82 (80.4%)	167 (81.5%)
	Yes	18 (17.5%)	20 (19.6%)	38 (18.5%)
DAY 4	n	103	96	199
	No	83 (80.6%)	77 (80.2%)	160 (80.4%)
	Yes	20 (19.4%)	19 (19.8%)	39 (19.6%)
DAY 5	n	102	95	197
	No	87 (85.3%)	85 (89.5%)	172 (87.3%)
	Yes	15 (14.7%)	10 (10.5%)	25 (12.7%)
DAY 6	n	103	92	195
	No	91 (88.3%)	81 (88.0%)	172 (88.2%)
	Yes	12 (11.7%)	11 (12.0%)	23 (11.8%)
DAY 7	n	102	91	193
	No	92 (90.2%)	85 (93.4%)	177 (91.7%)
	Yes	10 (9.8%)	6 (6.6%)	16 (8.3%)
DAY 8	n	101	90	191
	No	92 (91.1%)	85 (94.4%)	177 (92.7%)
	Yes	9 (8.9%)	5 (5.6%)	14 (7.3%)
DAY 9	n	100	89	189
	No	94 (94.0%)	84 (94.4%)	178 (94.2%)
	Yes	6 (6.0%)	5 (5.6%)	11 (5.8%)
Notos		. ()	- (/	/

Note:



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3k - Summary of and Statistical Analysis for Presence of Irritability/Confusion at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
		N 103	N 107	N 210
DAY 10	n	100	90	190
	No	96 (96.0%)	86 (95.6%)	182 (95.8%)
	Yes	4 (4.0%)	4 (4.4%)	8 (4.2%)
DAY 11	n	98	86	184
	No	93 (94.9%)	82 (95.3%)	175 (95.1%)
	Yes	5 (5.1%)	4 (4.7%)	9 (4.9%)
DAY 12	n	99	85	184
	No	97 (98.0%)	82 (96.5%)	179 (97.3%)
	Yes	2 (2.0%)	3 (3.5%)	5 (2.7%)
DAY 13	n	98	83	181
	No	96 (98.0%)	80 (96.4%)	176 (97.2%)
	Yes	2 (2.0%)	3 (3.6%)	5 (2.8%)
DAY 14	n	95	79	174
	No	94 (98.9%)	76 (96.2%)	170 (97.7%)
	Yes	1 (1.1%)	3 (3.8%)	4 (2.3%)

Note:



2.2 - Secondary Analysis

Table 2.2.3k - Summary of and Statistical Analysis for Presence of Irritability/Confusion at Day 1 to 14, ITT Population (continued)

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.15 (0.57; 2.34)	0.6963
Hesperidin vs Placebo at Day 7	0.65 (0.22; 1.88)	0.4250
Hesperidin vs Placebo at Day 10	1.12 (0.27; 4.65)	0.8797
Hesperidin vs Placebo at Day 14	3.71 (0.37; 37.03)	0.2634



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.31 - Summary of and Statistical Analysis for Presence of Diarrhea at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	85 (79.4%)	82 (78.1%)	167 (78.8%)
	Yes	22 (20.6%)	23 (21.9%)	45 (21.2%)
DAY 2	n	106	105	211
	No	84 (79.2%)	83 (79.0%)	167 (79.1%)
	Yes	22 (20.8%)	22 (21.0%)	44 (20.9%)
DAY 3	n	103	102	205
	No	87 (84.5%)	80 (78.4%)	167 (81.5%)
	Yes	16 (15.5%)	22 (21.6%)	38 (18.5%)
DAY 4	n	103	96	199
	No	90 (87.4%)	72 (75.0%)	162 (81.4%)
	Yes	13 (12.6%)	24 (25.0%)	37 (18.6%)
DAY 5	n	102	95	197
-	No	89 (87.3%)	76 (80.0%)	165 (83.8%)
	Yes	13 (12.7%)	19 (20.0%)	32 (16.2%)
DAY 6	n	103	92	195
	No	92 (89.3%)	72 (78.3%)	164 (84.1%)
	Yes	11 (10.7%)	20 (21.7%)	31 (15.9%)
DAY 7	n	102	91	193
	No	92 (90.2%)	76 (83.5%)	168 (87.0%)
	Yes	10 (9.8%)	15 (16.5%)	25 (13.0%)
DAY 8	n	101	90	191
	No	92 (91.1%)	77 (85.6%)	169 (88.5%)
	Yes	9 (8.9%)	13 (14.4%)	22 (11.5%)
DAY 9	n	100	89	189
	No	92 (92.0%)	81 (91.0%)	173 (91.5%)
	Yes	8 (8.0%)	8 (9.0%)	16 (8.5%)
Notos		- ()	, ,	/

Note:



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.31 - Summary of and Statistical Analysis for Presence of Diarrhea at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	94 (94.0%)	84 (93.3%)	178 (93.7%)
	Yes	6 (6.0%)	6 (6.7%)	12 (6.3%)
DAY 11	n	98	86	184
	No	94 (95.9%)	79 (91.9%)	173 (94.0%)
	Yes	4 (4.1%)	7 (8.1%)	11 (6.0%)
DAY 12	n	99	85	184
	No	96 (97.0%)	77 (90.6%)	173 (94.0%)
	Yes	3 (3.0%)	8 (9.4%)	11 (6.0%)
DAY 13	n	98	83	181
	No	94 (95.9%)	76 (91.6%)	170 (93.9%)
	Yes	4 (4.1%)	7 (8.4%)	11 (6.1%)
DAY 14	n	95	79	174
	No	91 (95.8%)	75 (94.9%)	166 (95.4%)
	Yes	4 (4.2%)	4 (5.1%)	8 (4.6%)

Note:



2.2 - Secondary Analysis

Table 2.2.31 - Summary of and Statistical Analysis for Presence of Diarrhea at Day 1 to 14, ITT Population (continued)

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.50 (0.73; 3.06)	0.2710
Hesperidin vs Placebo at Day 7	1.82 (0.77; 4.30)	0.1748
Hesperidin vs Placebo at Day 10	1.12 (0.34; 3.63)	0.8513
Hesperidin vs Placebo at Day 14	1.21 (0.29; 5.07)	0.7906



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3m - Summary of and Statistical Analysis for Presence of Anosmia at Day 1 to 14, ITT Population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	57 (53.3%)	62 (59.0%)	119 (56.1%)
	Yes	50 (46.7%)	43 (41.0%)	93 (43.9%)
DAY 2	n	106	105	211
	No	52 (49.1%)	56 (53.3%)	108 (51.2%)
	Yes	54 (50.9%)	49 (46.7%)	103 (48.8%)
DAY 3	n	103	102	205
	No	44 (42.7%)	50 (49.0%)	94 (45.9%)
	Yes	59 (57.3%)	52 (51.0%)	111 (54.1%)
DAY 4	n	103	96	199
	No	44 (42.7%)	48 (50.0%)	92 (46.2%)
	Yes	59 (57.3%)	48 (50.0%)	107 (53.8%)
DAY 5	n	102	95	197
	No	45 (44.1%)	45 (47.4%)	90 (45.7%)
	Yes	57 (55.9%)	50 (52.6%)	107 (54.3%)
DAY 6	n	103	92	195
	No	52 (50.5%)	43 (46.7%)	95 (48.7%)
	Yes	51 (49.5%)	49 (53.3%)	100 (51.3%)
DAY 7	n	102	91	193
	No	55 (53.9%)	48 (52.7%)	103 (53.4%)
	Yes	47 (46.1%)	43 (47.3%)	90 (46.6%)
DAY 8	n	101	90	191
	No	60 (59.4%)	50 (55.6%)	110 (57.6%)
	Yes	41 (40.6%)	40 (44.4%)	81 (42.4%)
DAY 9	n	100	89	189
	No	61 (61.0%)	51 (57.3%)	112 (59.3%)
	Yes	39 (39.0%)	38 (42.7%)	77 (40.7%)

Note:



2 - Efficacy Analysis2.2 - Secondary Analysis

Table 2.2.3m - Summary of and Statistical Analysis for Presence of Anosmia at Day 1 to 14, ITT Population

		Placebo N=109	Hesperidin N=107	All N=216
		N 103	11 107	
DAY 10	n	100	90	190
	No	63 (63.0%)	56 (62.2%)	119 (62.6%)
	Yes	37 (37.0%)	34 (37.8%)	71 (37.4%)
DAY 11	n	98	86	184
	No	63 (64.3%)	55 (64.0%)	118 (64.1%)
	Yes	35 (35.7%)	31 (36.0%)	66 (35.9%)
DAY 12	n	99	85	184
	No	65 (65.7%)	58 (68.2%)	123 (66.8%)
	Yes	34 (34.3%)	27 (31.8%)	61 (33.2%)
DAY 13	n	98	83	181
	No	65 (66.3%)	58 (69.9%)	123 (68.0%)
	Yes	33 (33.7%)	25 (30.1%)	58 (32.0%)
DAY 14	n	95	79	174
	No	64 (67.4%)	59 (74.7%)	123 (70.7%)
	Yes	31 (32.6%)	20 (25.3%)	51 (29.3%)

Note:



2.2 - Secondary Analysis

Table 2.2.3m - Summary of and Statistical Analysis for Presence of Anosmia at Day 1 to 14, ITT Population (continued)

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	0.78 (0.45; 1.35)	0.3686
Hesperidin vs Placebo at Day 7	1.05 (0.59; 1.86)	0.8711
Hesperidin vs Placebo at Day 10	1.03 (0.57; 1.87)	0.9124
Hesperidin vs Placebo at Day 14	0.70 (0.36; 1.37)	0.2952